William Aird/X
Jul 7, 2025, 11:42
What Drives Essential Thrombocythemia? Dr. William Aird on the Pathophysiology of Platelet Overproduction
Dr. William Aird, Professor of Medicine at Harvard Medical School, has posted on X:
“Essential Thrombocythemia (ET) Pathophysiology
ET is driven by one of 3 mutations:
- JAK2 V617F → cytokine-independent signaling
- CALR → abnormal MPL activation
- MPL → constitutive TPO receptor signaling
All lead to unchecked megakaryocyte proliferation and ↑ platelets.”
Curious about what drives Essential Thrombocythemia? Here’s a quick look at the mutations involved.
Explore more on Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?